News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: China's Life Science Deals Top $1.4 Billion For Week



8/21/2017 8:55:10 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Deals and Financings - Harbin Gloria Pharma and WuXi Biologics out-licensed ex-China rights for a PD-1 antibody to California's Arcus Biosciences in an $818 million deal;

- Shanghai's Zai Lab officially announced an IPO on the NASDAQ exchange that could raise as much as $115 million; - Lilly Asia Ventures closed its fourth China/Asia life science-focused fund at $450 million, a hard cap, according to China Money Network;
- Shanghai Ankon Technologies raised $100 million to market NaviCam, a swallow-able device for imaging the gastric track to diagnose gastric disorders;

- Shenzhen Royal Asset Management paid $33 million for China rights to three candidates aimed at fibrosis from Montreal's Prometic Life Sciences;

- Antengene, a one-year-old Shanghai startup, completed a $21 million series A round for in-licensings, led by Qiming Venture Partners;

- Ascletis of Hangzhou acquired China rights to a third HCV treatment from Medivir AB of Sweden, an addition to Ascletis' two other HCV treatments

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES